How to Get Wegovy in Florida: Telehealth, Prescriptions, and Pharmacy Access

Wegovy contains semaglutide 2.4 mg and is FDA-approved for weekly injection under the skin. Novo Nordisk developed it for chronic weight management in adults weighing enough to qualify: a BMI of 30 or higher, or 27 or higher if you also have a weight-related condition like hypertension or type 2 diabetes. Wegovy is distinct from Ozempic, which is semaglutide up to 2 mg formulated for type 2 diabetes, and different from compounded semaglutide available elsewhere, which has not received FDA approval. In Florida, obtaining Wegovy typically requires working with a prescriber (either at an office visit or by telehealth), finding a pharmacy with the medication available, and for most people with commercial insurance, completing a prior authorization step that frequently becomes the rate-limiting part of the process.

The useful question for most Florida patients is not whether a prescriber can be found, but whether insurance will pay for it. State law allows broad telehealth prescribing and does not restrict Wegovy to specialists, so access to a prescriber is rarely the bottleneck. Florida Medicaid does not cover Wegovy for weight management, and commercial plans generally require prior authorization with documented BMI, comorbidities, and often a lifestyle-intervention history. That insurance layer, not state prescribing law, determines whether most Florida residents get the brand-name drug, consider a compounded alternative, or pay cash.

Evidence boundary: what is established, what is not

Established: Wegovy's FDA approval, dosing schedule, and boxed warning language come from the FDA label. Florida Medicaid's non-coverage of Wegovy for weight management (as opposed to Ozempic for diabetes) is a widely reported state Medicaid formulary position, but formulary details change and should be confirmed against the current Florida Medicaid Preferred Drug List before a patient relies on it. Florida's expansion of nurse practitioner prescribing authority is a real, documented legislative change (HB 607, effective 2020), though the exact scope of "autonomous" practice varies by practice setting and should be confirmed with the Florida Board of Nursing rather than assumed to be unlimited.

Plausible but not verified in this draft: specific numeric claims about prior-authorization turnaround times, appeal overturn rates, pharmacy price differentials between chains, and current national Wegovy supply status are commonly repeated in patient-facing content but could not be traced to a verifiable primary source for this article. They are described below in general terms rather than presented as fixed figures, and an editor with access to current payer and pharmacy data should verify or replace them before publication.

Not established: any claim about a specific insurer's Florida-specific policy, a specific pharmacy's current price, or a specific compounding pharmacy's current turnaround time. These vary by plan, location, and month, and none should be stated as fact without a dated, named source.

Who can prescribe Wegovy in Florida

Florida does not restrict Wegovy prescribing to a single specialty. Physicians (MD/DO), nurse practitioners, and physician assistants can all prescribe it as part of ordinary medical practice, subject to their state license and, for PAs, their supervisory agreement. Florida nurse practitioners gained expanded prescribing authority under state legislation passed in 2019 and effective in 2020; the practical effect is that a primary care NP can evaluate a patient and prescribe Wegovy without a physician co-signature in many settings. Semaglutide is not a federally scheduled controlled substance, so it does not carry the extra DEA-related restrictions that apply to controlled-substance telehealth prescribing.

What this means for a patient: eligibility depends on meeting the FDA label's BMI and comorbidity criteria and on a documented clinical evaluation, not on seeing an endocrinologist or obesity-medicine specialist specifically.

Telehealth access

Florida permits telehealth prescribing of both controlled and non-controlled prescription drugs under state telehealth law, and Wegovy is commonly prescribed this way. Typical telehealth workflows for GLP-1 medications involve an online intake, a real-time video visit with a Florida-licensed prescriber, and electronic routing of the prescription to a retail or mail-order pharmacy. Because the exact statutory requirements for the initial encounter (for example, whether an audiovisual visit is mandatory in every case) can change with legislative updates, a patient or clinician relying on the specific mechanics of the law should confirm current requirements against the Florida statutes and the Florida Board of Medicine or Board of Nursing rather than a secondary summary.

Reasonable contraindication screening before starting a GLP-1 agonist, regardless of visit format, includes personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, and a history of pancreatitis, all of which appear in the FDA label's warnings and precautions.

Insurance coverage and prior authorization

Most Florida commercial plans that cover Wegovy require prior authorization. A typical PA request documents current BMI (often within the past 90 days), any qualifying comorbidity, and sometimes evidence of a prior attempt at lifestyle intervention or a prior weight-management medication trial. Turnaround times, appeal success rates, and exact documentation requirements vary by plan and are not something this article can state as fixed numbers; a patient should ask their specific plan for its GLP-1 prior authorization criteria and expected timeline, and the prescriber's office can usually provide that plan-specific detail faster than a general guide can.

Florida Medicaid does not cover Wegovy for chronic weight management as of this writing. Medicaid coverage of semaglutide in Florida applies to the type 2 diabetes indication (marketed as Ozempic), not the weight-management indication. Formulary decisions can change, so a patient on Florida Medicaid should confirm current coverage directly with their plan rather than relying on this statement indefinitely.

Labs before starting Wegovy

No specific baseline lab work is required by the FDA label before you start Wegovy, but many prescribers order tests to screen for potential concerns and monitor how your metabolism responds. Standard checks typically include HbA1c or a fasting glucose measurement to establish your current blood sugar control, lipid levels, and a comprehensive metabolic panel to assess kidney and liver function (the label notes there is limited safety data for people with significant kidney problems). Thyroid function testing is also common because the label carries a boxed warning about thyroid C-cell tumors that appeared in rodent studies, though this warning reflects findings in animals and no proven connection has been confirmed in people. A lipase test is sometimes ordered as well, since GLP-1 drugs are linked to rare pancreatitis. These testing decisions are left to your prescriber's judgment rather than being standardized, so the specific labs checked will depend on who treats you.

Compounded semaglutide and 503A pharmacies

Florida-licensed 503A pharmacies can compound medications for individual patients under a valid prescription, subject to Florida Board of Pharmacy oversight. Two points matter for anyone considering this route:

Compounded semaglutide is not Wegovy. It is not FDA-approved, is not manufactured by Novo Nordisk, and has not undergone the FDA's premarket review of safety, effectiveness, and manufacturing quality. The FDA's public guidance on compounding states plainly that compounded drugs "have not been found by FDA to be safe, effective, and manufactured in accordance with federal quality standards."

Compounding a commercially available drug is legally narrow. Under federal law, a 503A pharmacy generally may compound a version of a drug that is already commercially available only when a prescriber documents a specific clinical need for that individual patient (for example, an allergy to an inactive ingredient), or when the FDA has listed the drug as being in an official shortage. Whether Wegovy or its active ingredient is currently listed as in shortage changes over time and should be checked against the FDA's current drug shortage database rather than assumed from past reporting, since national supply conditions for GLP-1 medications have shifted multiple times since 2022.

Anyone considering a compounded product should confirm the pharmacy's Florida Board of Pharmacy license, ask whether the semaglutide is sourced from an FDA-registered facility, and ask whether the pharmacy performs independent potency and sterility testing on sterile injectable batches.

Cost without insurance

Brand-name Wegovy's list price has historically been over $1,000 per 28-day supply in the United States, and Florida retail pricing is generally consistent with national list pricing since most chain pharmacies do not set independent list prices. Novo Nordisk has offered manufacturer savings programs for commercially insured patients in the past, but eligibility, discount amount, and exclusions for government-funded insurance (Medicare, Medicaid, Tricare) change over time and should be confirmed on the manufacturer's current program page before a patient counts on a specific discount. Compounded semaglutide is generally advertised at a lower monthly price than brand-name Wegovy, but price alone does not offset the regulatory and quality differences described above.

Because prices, manufacturer program terms, and even which pharmacies stock the drug change frequently, none of the specific dollar figures a patient may see elsewhere online should be treated as current without checking a dated source at the time of the decision.

Storage in Florida's climate

Unopened Wegovy pens require refrigeration at 36°F to 46°F (2°C to 8°C). Once a pen is in use, the FDA label allows storage at room temperature up to 86°F (30°C) for a limited number of days, after which the pen should be discarded even if medication remains. Florida's outdoor and in-vehicle temperatures routinely exceed that threshold for much of the year, so patients should avoid leaving pens in a car, mailbox, or unattended porch delivery, use an insulated pouch with a cold pack for transport, and consider requesting signature-required delivery for mail-order shipments during summer months. Exact allowable in-use storage duration and temperature limits should be confirmed against the current FDA label, since labeling can be revised.

Transferring a prescription into Florida

Florida law generally allows pharmacies to transfer prescriptions, including remaining refills, from an out-of-state pharmacy to a Florida pharmacy, following standard interpharmacy transfer procedures. A patient moving to Florida or splitting time between states should contact the new Florida pharmacy with the name and phone number of the pharmacy currently holding the prescription. If a move also triggers a change in health insurance, a new prior authorization may be required under the new plan even if the prescription itself transfers without issue. Continuity gaps in GLP-1 therapy can be associated with resumption of appetite and some regain of weight after discontinuation, based on general clinical experience with this drug class, though the exact time course varies by individual and is not something this article can specify without a directly supporting study; a prescriber can advise on timing for an individual patient.

Verification checklist: stable facts vs. facts that change

Use this to separate what a Florida patient can treat as durable versus what must be re-checked at the time of the decision, since much of the confusion around GLP-1 access comes from treating date-sensitive information as if it were fixed.

Stable (federal label and clinical facts, unlikely to change month to month)

• Wegovy's FDA-approved indication (chronic weight management, adults meeting BMI/comorbidity criteria) and its distinction from Ozempic.
• The drug's mechanism as a GLP-1 receptor agonist and its route of administration (weekly subcutaneous injection).
• The boxed warning regarding thyroid C-cell tumors in rodent studies and the associated contraindications (personal/family history of medullary thyroid carcinoma, MEN 2).
• The refrigeration requirement for unopened pens and the general concept of a limited room-temperature window for in-use pens.
• Florida's general legal framework allowing NP and PA prescribing and telehealth prescribing of non-scheduled drugs.

Date-sensitive and requires re-verification before relying on it

• Whether Wegovy or its active ingredient is currently listed on the FDA drug shortage database (affects legal compounding scope).
• Florida Medicaid's current formulary position on Wegovy and any pilot coverage changes.
• Any specific commercial insurer's Florida prior authorization criteria and current turnaround time.
• Manufacturer savings card terms, maximum benefit amount, and eligibility exclusions.
• Cash and insurance-negotiated prices at any named pharmacy chain.
• Current national or regional supply status for any Wegovy dose strength.
• The exact current text of Florida's telehealth statute provisions on initial-visit requirements.

How to use this before a Florida appointment or pharmacy call

1. Confirm your own BMI and any qualifying comorbidity with a recent clinical visit; this documentation drives both eligibility and prior authorization.
2. Call your insurer (or ask the prescriber's office to check) for the plan's current Wegovy prior authorization criteria rather than relying on a general average.
3. Call the specific pharmacy to confirm current stock before the prescription is sent electronically.
4. If considering a compounded product, ask the pharmacy directly whether it is compounding under an individual clinical-difference determination or under an active FDA shortage listing, and ask for its current Florida Board of Pharmacy license status.
5. Re-check Novo Nordisk's savings program page directly for current eligibility and discount terms rather than a number quoted elsewhere.

When to seek urgent care instead of waiting on access logistics

Severe abdominal pain (possible pancreatitis), persistent vomiting with signs of dehydration, symptoms of a severe allergic reaction, or a new neck mass or hoarseness (relevant given the thyroid warning) warrant urgent medical evaluation rather than waiting for a telehealth follow-up or pharmacy delivery. None of the access logistics described above should delay care for a concerning new symptom.

Note for reviewers: this draft removed a direct quotation previously attributed to a named physician because the underlying source could not be verified from the material provided. It also removed or narrowed several precise statistics (prior authorization turnaround times, appeal overturn rates, specific chain pharmacy prices, and a cited "Q4 2024 earnings call" figure) that were attached to mismatched or unverifiable citations in the source draft. These should be restored only with a verifiable, dated, Florida-specific source. This article has not yet received qualified medical review.